Australia is carefully awaiting the arrival of retatrutide, a novel dual GIP and GLP-1 receptor agonist that's generating significant buzz in the global weight management landscape. Developed by Novo Nordisk, this https://kallumxdnw417222.hyperionwiki.com/2475766/this_new_drug_retatrutide_australia_a_promising_hope_for_obesity_treatment